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Objectives The purpose of this study was to investigate the frequency and clinical impact of incomplete left atrial append-
age (LAA) sealing and consequent peri-device residual blood flow in patients undergoing percutaneous LAA clo-
sure with the Watchman device (Atritech, Inc., Plymouth, Minnesota).
Background During percutaneous LAA closure for stroke prophylaxis, the geometric variability of the LAA ostium may result
in an incomplete seal of the LAA. On the one hand, this could enhance thrombus formation and embolization of
thrombi around the device into the circulation; on the other hand, the relatively small size of these leaks may
preclude clinically relevant embolizations.
Methods Patients randomly assigned to device implantation in the PROTECT AF (Percutaneous Closure of the Left Atrial Ap-
pendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial were analyzed.
Transesophageal echocardiography was performed at 45 days, 6 months, and 12 months. Per the study protocol,
patients discontinued warfarin therapy if the 45-day Transesophageal echocardiogram revealed either minimal or no
peri-device flow (jet 5 mm width). The impact of peri-device flow severity, defined as minor, moderate, or major
(1 mm, 1 mm to 3 mm, 3 mm, respectively) on the composite primary efficacy endpoint (stroke, systemic embo-
lism, and cardiovascular death) is expressed as hazard ratio (HR) with 95% confidence interval (CI).
Results Transesophageal echocardiography follow-up revealed that 32.0% of implanted patients had at least some degree of
peri-device flow at 12 months. The HR of the primary efficacy endpoint per 1 mm larger per-device flow was 0.84
(95% CI: 0.62 to 1.14; p  0.256). Compared to patients with no peri-device flow, the HRs were 0.85 (95% CI: 0.11
to 6.40), 0.83 (95% CI: 0.33 to 2.09), and 0.48 (95% CI: 0.11 to 2.09) for minor, moderate, and major peri-device
flow, respectively (p  0.798). Compared to patients with no peri-device flow who discontinued warfarin, the HR for
patients with any peri-device flow and continuing warfarin was 0.63 (95% CI: 0.14 to 2.71; p  0.530).
Conclusions These data indicate that residual peri-device flow into the LAA after percutaneous closure with the Watchman
device was common, and is not associated with an increased risk of thromboembolism. This finding should be
interpreted with caution as the low event rate decreases the confidence of this conclusion. (J Am Coll Cardiol
2012;59:923–9) © 2012 by the American College of Cardiology Foundation
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Peri-Device Leak After Watchman Implantation March 6, 2012:923–9Atrial fibrillation (AF) causes 15%
to 20% of ischemic strokes, and
the overall risk of stroke in patients
with nonvalvular AF is as high as
5% per year (1). Warfarin has long
been the cornerstone for decreas-
ing risk of stroke in patients with
AF, and its efficacy has been well
established (2,3). However, the
risk of bleeding, inconvenience of
frequent monitoring and dose ad-
justments, drug interactions, and restrictions on diet and
alcohol intake perhaps explain why warfarin discontinuation
rates are estimated to be as high as 38% per year (3). Other
ovel anticoagulants are also in various stages of development
nd clinical use, but all oral medication therapy is limited by
he drug-specific incidence of side effects, and the patient-
pecific propensity for bleeding from these systemically admin-
stered agents (4–8).
Autopsy and surgical data have suggested that 90% of
trial thrombi in nonvalvular AF patients originate from the
eft atrial appendage (LAA) (9). Accordingly, devices that
an isolate this structure from the systemic circulation to
bviate the need for long-term systemic anticoagulation
herapy have been developed. The critical role of the LAA
n stroke pathogenesis was recently demonstrated by the use
f the Watchman LAA closure device (Atritech, Plymouth,
innesota) in the PROTECT AF (Percutaneous Closure
f the Left Atrial Appendage Versus Warfarin Therapy for
revention of Stroke in Patients With Atrial Fibrillation)
tudy (10). In this multicenter trial, nonvalvular AF patients
ith a CHADS2 (acronym for congestive heart failure,
hypertension, age 75 years, diabetes mellitus, and prior
stroke or transient ischemic attack) risk score 1 were
randomly allocated to either standard warfarin therapy or
percutaneous implantation of the LAA closure device. As
per the protocol design, patients undergoing LAA closure
continued warfarin for at least 45 days; transesophageal
echocardiogram (TEE) confirmation of LAA closure trig-
gered cessation of warfarin therapy and institution of
clopidogrel therapy to the 6-month timepoint, with life-
long aspirin therapy. Using the pre-determined primary
composite efficacy endpoint of stroke, systemic emboliza-
tion or cardiovascular death, this study demonstrated non-
inferiority of the LAA closure strategy as compared to usual
warfarin therapy.
To understand some of the technical limitations of LAA
closure, it is important to consider the anatomical variations
of the LAA. There is a wide range of LAA ostial diameters
date, no royalties have been received. Dr. Reddy has received clinical research
grant support and consultant fees from Atritech, Inc. All other authors have
reported they have no relationships relevant to the contents of this paper to
disclose.
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LAA  left atrial
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TEE  transesophageal
echocardiogramb
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2011, accepted November 8, 2011.and lengths, and most importantly, the morphology of the
LAA ostium is elliptical rather than round (11). The
Watchman device comes in a finite number of sizes and has a
round shape. While the device has 10 individually articulating
splines to permit a more oval shape to accommodate LAA
orifices that are not perfectly circular, there is a limit to its
deformability. This is potentially of concern as a round implant
into an oval-shaped orifice may lead to incomplete sealing of
the orifice (12). That could create a pouch with stagnant blood
flow, which could enhance thrombus formation and emboli-
zation of thrombi past the device into the circulation—
potentially leading to further stokes (13). Indeed, incomplete
occlusion of the LAA has been a concern during surgical
ligation (14,15). Conversely, it is possible that with LAA
device implantation, the presence of a small area of incomplete
sealing may not potentiate any clinically relevant embolization.
That is, any large embolic thrombi that might develop may not
be able to pass around the device and out of the LAA, provided
that the size of the leak is small.
As a practical acknowledgement of the size and shape
mismatch between the LAA ostium and the Watchman
device, the PROTECT AF trial design defined “LAA closure”
as any seal with 3 mm width (2 mm) of peri-device flow.
hat is, LAA closure with the Watchman device was deemed
uccessful even in cases with a residual gap of up to 5 mm
round the device. This degree of “acceptable” peri-device flow
as chosen as a reasonable cut-off value but the long-term
linical consequences of such flow were unknown. The fre-
uency of peri-device LAA flow because of an incomplete
AA seal, and its consequent clinical effect remains unclear.
nderstanding the clinical impact of incomplete closure of the
AA would be critical when assessing thromboembolic risk
ost-implantation. Consequently, this manuscript details a
ost-hoc analysis of the Watchman implantation cohort in the
ROTECT AF study to study the incidence and natural
istory of peri-device flow, and to determine its functional
mpact on clinical outcomes.
ethods
ata collected prospectively from the patients who were
andomly assigned to the Watchman device in the PROTECT
F trial and followed up for the full duration of the trial
ere used for this retrospective analysis. After the device
ad been implanted, patients were treated with warfarin for
5 days. The TEE imaging was performed at 45 days, 6
onths, and 12 months to assess for residual peri-device
ow and device stability and positioning. Patients discon-
inued warfarin therapy if the 45-day TEE showed either
omplete sealing of the LAA or if there was residual
eri-device flow 3  2 mm width, that is, 5 mm. All
atients received clopidogrel from 45 days to 6 months after
mplantation and life-long aspirin.
evice. The Watchman LAA closure device is composed
f a self-expanding nitinol frame structure with fixation
arbs and a permeable polyester fabric (Fig. 1) that covers
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March 6, 2012:923–9 Peri-Device Leak After Watchman Implantationthe surface of the device facing the left atrium. Currently,
the device is available in 5 sizes ranging in maximal diameter
from 21 mm to 33 mm. For any given patient, the device
size is chosen to be 10% to 20% larger than the diameter of
the LAA ostium to ensure sufficient and stable positioning
of the device.
Endpoints. The composite primary endpoint for efficacy
onsisted of the occurrence of stroke (including ischemic or
emorrhagic stroke), systemic embolism, or cardiovascular
r unexplained death. Follow-up visits occurred at 45 days,
t 6 and 12 months, and twice a year thereafter. Neurolog-
cal assessments were performed at baseline, 12 months, and
4 months, and whenever a neurological event occurred.
eak severity and events. Color Doppler by multiplane
TEE was used to check for any communication between the
atrium and the LAA and to determine peri-device flow
width (Fig. 2). For the purposes of the present analysis,
peri-device flow severity was defined as minor (1 mm),
moderate (1 mm to 3 mm) or major (3 mm). When the
PROTECT AF study began enrollment in 2005, the core
laboratory responsible for reviewing images was St. Louis
University Core Lab Echocardiography Laboratory. In July
2006, Duke Clinical Research Institute assumed responsi-
bility as the core laboratory. Data are based on the 1,500
patient-year dataset and the final core laboratory data. Study
centers followed a standard imaging protocol to record TEE
views in a consistent manner across all centers. The echo-
cardiography core laboratory over-read all baseline and
follow-up imaging to provide LAA measurements, peri-
device flow, and device position.
Statistical analysis. The original sample size for the
Figure 1 LAA Ostium by 3-Dimensional TEE and Watchman Dev
(A) Shown is the Watchman filter device; notice the 10 equally-spaced struts, eac
shape (small arrows). These 2 illustrations highlight the discrepancy between the
turn explains the reason for incomplete sealing (large arrow) and residual blood flROTECT AF trial was based on a planned aggregate ofetween 600 and 1,500 patient-years of follow-up, a 2-fold
oninferiority margin, and a desire for 80% power under a
ate of 6.15 events per 100 patient-years. As a logical
onsequence of the original study design, this subanalysis
as relatively limited power. Means, standard deviations,
inimums, maximums, or counts and percentages are used
or descriptive statistics. Trends in echocardiography mea-
urements over time were modeled with generalized linear
ixed models, accounting for the repeated measurements
n subjects over time, with a binomial or multinomial link
unction as appropriate. Time in these models was treated as
factor with 3 levels, which allows for departures from
inear changes. In analyses relating echocardiography mea-
urements to clinical events, the time-to-event was calcu-
ated from the date of the 45 day visit. Event rates were
ompared by proportional hazards regression and Poisson
egression models, with the logarithm of follow-up time as
n offset term for the latter. Hazard ratios (HR)1 indicate
n increased risk of a primary efficacy event. To include a
ufficient number of events for the time-to-event analyses,
atients without peri-device flow were attributed to have
ow of size zero. All p values are 2-sided, and values  0.05
are considered statistically significant.
Results
Patient population. Of the 485 patients with a successfully
implanted Watchman device, 445 had a 45-day visit with
TEE data adjudicated by the echocardiography core labo-
ratory data and without an efficacy event before the 45-day
visit. During follow-up of the 445 patients included in this
a small anchoring time. (B) Third-generation Watchman device with spherical
of the left atrial appendage (LAA) ostium and the Watchman device, which in
some of the patients. TEE  transesophageal echocardiography.ice
h with
shape
ow inanalysis, 414 and 389 patients had 6-month and 12-month
et
a
A
f
L
c
i
b
m
m
w
m
d
b
P
v
9
l
d
t
0
t
p
m
a
926 Viles-Gonzalez et al. JACC Vol. 59, No. 10, 2012
Peri-Device Leak After Watchman Implantation March 6, 2012:923–9follow-up TEEs, respectively, analyzed by the core labora-
tory. A total of 5 patients in the PROTECT AF study
(0.9%) sustained a stroke during the procedure. The inci-
dence of pericardial effusion was 5.2%. The device emboli-
zed in 3 patients (0.6%). Device-associated thrombus was
observed in 15 of 445 successfully implanted patients
(3.4%). Of these patients, only 2 had experienced an
ischemic stroke (0.45% of patients, 0.17 events per 100
patient-years); the other patients were either asymptomatic
or endothelialized with continued anticoagulation therapy
for 3 to 6 months. Other procedure- or device-related safety
vents in the PROTECT AF study were bleeding (n  4),
bruising/hematoma (n  2), arteriovenous fistula (n  1),
arrhythmia (n  1), and other events (n  3: esophageal
ear from the TEE probe, elective removal of the device,
nd hemopericardium requiring transfusion).
natomic characteristics of the LAA at implantation and
ollow-up. There was a wide variation on the size of the
AA ostium width and length at baseline, underscoring the
hallenges of occluding the LAA with a device that comes
n a finite number of sizes. The mean LAA ostium width at
aseline was 21.9  4.1 mm, with a maximum and
inimum size of 12.1 mm and 38.8 mm, respectively. The
ean LAA ostium length at baseline was 49.4  9.1 mm,
ith a maximum and minimum size of 24.9 mm and 85.7
m, respectively. Tables 1 and 2 summarize patients’
emographics and the anatomic parameters of the LAA at
aseline.
revalence of peri-device flow. As shown in Table 3, the
Figure 2 Peri-Device Leak by TEE Imaging
The transesophageal echocardiogram (TEE) illustrates the existence of incomplete
with peri-device residual flow noted by color Doppler (large arrows).ast majority of the 45-day TEEs (419 of 445 patients,4.2%) were of sufficient quality to be included in the core
aboratory analysis. The prevalence of any flow around the
evice decreased with time from 40.9% at the 45-day TEE,
o 33.8% at 6 months, and to 32.1% at 12 months (p 
.001). Among patients who had documented residual flow,
he severity of the flow was minor in only a small percent of
atients (7.7%). Moderate and major peri-device flow were
ost frequent (59.9% and 32.4%, respectively). The mean
nd maximum width of the leak measured were 2.8 and 6.2
g of the left atrial appendage (LAA)
Patient DemographicsTable 1 Patient Demographics
Age, yrs 72 9
Male 70
Race
Asian 1
Black 2
White 92
Hispanic 5
Pacific Islander 1
Other 1
CHADS2 score 2.2 1.2
CHADS2 score distribution
1 33
2 34
3 19
4 8
5 4
6 1
Values are mean  SD or %.sealinCHADS2  congestive heart failure, hypertension, age 75 years, diabetes mellitus, and prior
stroke or transient ischemic attack.
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March 6, 2012:923–9 Peri-Device Leak After Watchman Implantationmm, 2.9 and 6.8 mm, and 2.9 and 6.0 mm, at 45 days, 6
months, and 12 months of follow-up, respectively. This
distribution of peri-device flow severity did not appreciably
change over the 6- and 12-month timepoints (p  0.731).
eri-device flow and clinical outcomes. The primary
utcome was determined as a function of both the presence
f any peri-device flow as well as the severity of the flow. To
he former, the primary efficacy event rate was not signifi-
antly different between patients with no peri-device flow
2.8%, or 18 events per 642 patient-years) versus patients
ith any peri-device flow (2.0%, or 9 events per 450
atient-years; p  0.635). As shown in Figure 3, there was
lso no statistical interaction between the severity of the
eri-device flow and the primary endpoint. In addition to
he primary composite endpoint of the PROTECT AF
tudy, we also assessed a composite embolic endpoint of stroke
nd systemic embolization. Again, there was no significant
tatistical relationship between the presence or severity of
eri-device flow and this clinical endpoint (Fig. 3).
Baseline Descriptive Anatomyof L ft Atrial Ap endageTable 2 Baseli e D scriptive Anatomyof Left Atrial Appendage
Anatomy of LAA Baseline TEE
Maximum LAA ostium width, mm
Mean  SD 21.9 4.1
Minimum, maximum 12.1, 38.8
Maximum LAA ostium length, mm
Mean  SD 49.4 9.1
Minimum, maximum 24.9, 85.7
LAA area measured at 0°, mm2
Mean  SD 580.0 204.8
Minimum, maximum 173.0, 1261.0
LAA pulsed wave peak velocity, cm/s
Mean  SD 35.5 18.4
Minimum, maximum 1.4, 117.2
LAA  left atrial appendage; TEE  transesophageal echocardiography.
Prevalence of Peri-Device Flow and Flow SeveritTable 3 Prevalence of Peri-Device Flow and
45 Days
TEE evaluations 445
Flow around device filter (%)
Yes 182 (40.9)
No 237 (53.3)
Unable to evaluate 18 (4.0)
Field not completed 8 (1.8)
If leak present
Flow severity (%)
Minor 1 mm 14 (7.7)
Moderate 1–3 mm 109 (59.9)
Major 3 mm 59 (32.4)
Flow measurement, mm
Mean  SD 2.8 1.0
Minimum, maximum 0.9, 6.2
Values are n, n (%), mean SD. *The p values are for tests of differen
measures on subjects. The models examined prevalence of yes versus
flow measurement.
TEE  transesophageal echocardiography.Of the 445 patients who underwent TEEs at 45 days, 59
atients (13%) continued warfarin treatment for some
dditional period. The reason for continuing warfarin was
eri-device flow in 38 patients (64%), physician order in 13
atients (22%), and “other” in 8 patients (14%). For patients
ho did not continue warfarin, the primary efficacy event
ates (expressed as events per 100 patient-years) were 2.1 (7
f 338) for patients with any peri-device flow compared to
.8 (17 of 601) for patients with no peri-device flow (p 
.486) (Table 4). When analyzing the events of patients who
ontinued anticoagulation therapy beyond 45 days, the event
Follow-Up TEESeverity On Follow-Up TEE
6 Months 12 Months p Value
414 389
140 (33.8) 125 (32.1) 0.001
253 (61.1) 249 (64.0)
19 (4.6) 15 (3.9)
2 (0.x5) 0 (0.0)
4 (2.9) 1(0.8) 0.275
84 (60.0) 78 (62.4)
52 (37.1) 46 (36.8)
2.9 1.1 2.9 1.0 0.902
0.8, 6.8 1.1, 6.0
r time from generalized linear mixed models, accounting for repeated
eri-device flow, prevalence of minor/moderate/major flow, and mean
Figure 3 Primary Efficacy Endpoint Rates by Leak Severity
Comparison of primary efficacy (dark blue bars), ischemic stroke (medium blue
bars), and a composite endpoint of stroke and systemic embolization (light
blue bars), showing no significant statistical relationship between the presence
or severity of peri-device flow.y OnFlow
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Peri-Device Leak After Watchman Implantation March 6, 2012:923–9rate was 2.4 events per 100 patient-years (1 of 41) for patients
without peri-device flow and 1.8 events per 100 patient-years
(2 of 112) for patients with peri-device flow (p  0.802).
Association of peri-device flow size and clinical events. The
HR for the primary efficacy events per 1 mm increase in the
leak size was 0.84 (95% confidence interval [CI]: 0.62 to
1.14; p  0.256). For patients who did not continue
warfarin, the HR was 0.74 (95% CI: 0.31 to 1.79) for
patients with any peri-device flow as compared to patients
with no flow (p  0.509). When compared to patients with
o flow, the HRs were 0.85 (95% CI: 0.11 to 6.40), 0.83
95% CI: 0.33 to 2.09), and 0.48 (95% CI: 0.11 to 2.09) for
atients with minor, moderate, and major peri-device flow,
espectively (p  0.798). In sum, there is no clear interac-
ion among either peri-device flow severity or warfarin use
nd the subsequent risk of clinical events.
iscussion
he main finding of this study is the lack of interaction
etween residual flow around the LAA closure device and
linical outcome, including thromboembolic events, in a
arge sample of patients. Patients with peri-device flow did
ot experience a higher rate of events, and continued
nticoagulation therapy did not significantly decrease the
rimary event rate compared to that of patients who
iscontinued anticoagulation. Although the results suggest
hat it might be safe to stop anticoagulation therapy at 45 days
egardless of the presence of peri-device flow, these findings
hould be construed with caution. This retrospective analysis
ay also be confounded by continued anticoagulation therapy
n some patients with residual flow. These data suggest the
afety of warfarin discontinuation after Watchman implanta-
ion regardless of the presence of the residual peri-device flow,
rovided that the size of the leak is5 mm. Furthermore, the
ncreased experience of our operators, which has been shown to
mprove the safety of the procedure (16), should be taken into
ccount when interpreting the results of our study.
The multiple problems associated with anticoagulant
herapy have led to a search for alternative approaches for
troke prevention in AF. These approaches are predicated
n the fact that in nonvalvular AF, the embolus is thought
o originate from the LAA in the majority of cases (4). That
as led to a strategy of mechanically excluding the LAA
rom the systemic circulation (17). Until recently, the
enefit of LAA exclusion on reducing stroke risk had not
Primary Efficacy Event Rates According to Peri-Table 4 Primary Efficacy Event Rates Accor
Group n (Even
No flow, discontinued warfarin 245 2.
No flow, continued warfarin 18 2.
Any flow, discontinued warfarin 141 2.
Any flow, continued warfarin 41 1.
CI  confidence interval.een rigorously compared with anticoagulation therapy inatients with nonvalvular AF. However, the PROTECT
F trial, which demonstrated the noninferiority of LAA
losure with the Watchman device to anticoagulation ther-
py, has sparked intense interest in LAA exclusion strate-
ies. Although a number of complications have been re-
orted associated with endovascular device placement, these
re largely experience-related events that have diminished in
umber and importance with increased operator experience
16). Nevertheless, an issue that remains a concern is the
ismatch between the circular device and the typically oval
AA orifice, the subsequent inadequacy of circumferential
AA sealing, and the implications this has for the necessity
or ongoing anticoagulation therapy (7).
The problem of incomplete occlusion of the LAA has
een reported even when this procedure is performed
urgically (7). With any of the surgical techniques, there is
significant risk of incomplete exclusion, ranging from 10%
o 72% depending upon the surgical technique utilized and
he definition of surgical failure (14,15). There are fewer
ata on the true closure rates of percutaneously placed
evices. In the recently published PLAATO (Percutaneous
eft Atrial Appendage Transcatheter Occlusion) follow-up
tudy, the investigators report a prevalence of incomplete
closure” of only 10% at 2 months; however, “closure” was
efined as successful if the leak was 3 mm. Furthermore,
hese data were largely derived from a few large-volume
xperiences, and were not independently adjudicated by a
ore echocardiography laboratory. Indeed, the true closure
ate for the PLAATO device—that is, closure as defined as
ero flow—may be considerably less than this. In our own
xperience of 25 patients followed up for 5 years after
LAATO implantation, the true closure rate was only
25% (submitted for publication) (10,18,19).
The interaction of incomplete occlusion of the LAA and
isk of thromboembolism remains poorly understood. All
he available evidence comes from small studies using
ifferent surgical closure techniques that are usually associ-
ted with modified Maze, coronary bypass, or valvular
urgery (14,15). Kanderian et al. (20) reported that there
Primary Efficacy Event Rates inatients With and Withou Peri-Device FlowTable 5 Primary Efficacy Event Rates inPatients With and Without Peri-Device Flow
Any Residual Flow No Flow p Value
Efficacy 9/182 (5%) 18/263 (7%) 0.572
Ischemic stroke/systemic 5/182 (3%) 11/263 (4%) 0.669
e Flow and Warfarin Useto Peri-Device Flow and Warfarin Use
ient-Yrs)
Hazard Ratio
(95% CI) Overall p Value
601) 1.00 0.857
1) 0.89 (0.12–6.73)
38) 0.74 (0.31–1.79)
12) 0.63 (0.14–2.71)Devicding
Rate
ts/Pat
8 (17/
4 (1/4
1 (7/3
8 (2/1embolism
11
1
1
1
1
1
1
1
1
2
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March 6, 2012:923–9 Peri-Device Leak After Watchman Implantationwas no difference of stroke rate among patients with
successful closure versus incomplete closure. Perhaps the
association of incomplete surgical closure and presence of
LAA thrombus may be due to the inherent thromboembolic
risk of these surgical patients (valvular disease, Maze pro-
cedure, post-operative state). In our analysis, the presence of
peri-device flow using the Watchman device was not
associated with the development of LAA-related thrombo-
embolic events. Hence, this intracardiac device approach in
patients with nonvalvular AF appears to carry a different risk
of stroke than after surgery when there is incomplete LAA
closure.
Study limitations. It should be underscored that the main
limitation of this analysis arises from its retrospective nature
and relatively limited number of events, which in turn limits
the power of the analysis; that is reflected by the wide
confidence interval around the hazard ratio. A study with a
larger sample size or a study with higher event rates would
likely narrow the confidence interval and make the results
more definitive. Therefore, our conclusions should be con-
sidered strictly hypothesis generating. Nevertheless, the
strength of the data is that this cohort from the PROTECT
AF study is the largest sample available, and it is the first
report studying stroke risk in patients with incomplete LAA
closure. It is also important to recognize that it is not known
whether the principles of this study can be applied to other
percutaneous device- or suture-based approaches. That is,
while it would be reasonable to conclude from these data
that minimal leak around the Watchman device does not
portend worse prognosis, the same may or may not be true
with other devices. Any substantial differences in the ana-
tomical crevices associated with another device (different
from the Watchman device) might have a different out-
come. Thus, data on leak past the closure strategy should be
collected for each new device and approach. Table 5.
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